|
Peptides
DRAK1 Peptide
Background
DRAK1 (N-Terminus) Peptide
Location
15 amino amino terminus of human DRAK1.
Application
DRAK1 peptide is used for blocking the activity of Anti-DRAK1 (Cat. No. 2147). Incubating the peptide with equal volume of antibody for 30 min at 37˚C usually completely blocks the antibody activity in Western blotting.
Tested Application
Bl
Buffer
PBS containing 0.02% sodium azide
Storage
DRAK1 peptide is supplied as 200 μg/ml, 50 μg/vial, in PBS pH7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide. Store at -20˚C, stable for one year.
Species Reactivity
n/a
Species
H
Short Description
(NT) DRAK1 peptide
This product belongs to the following categories:
Related Products
References- Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995;270:13757-65
- Huang J, Gao X, Li S, Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A 1997;94:12829-32
- Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem 1997;272:7727-31
- Hofmeister R, Wiegmann K, Korherr C, Bernardo K, Kronke M, Falk W. Activation of acid sphingomyelinase by interleukin-1 (IL-1) requires the IL-1 receptor accessory protein. J Biol Chem 1997;272:27730-6 (RD1299)
Datasheet 0801-W
|
|
